Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-ASA Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Aspirin Resistance in Systemic Lupus Erythematosus (SLE)

NCT00731302
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
aspirin and meloxicam
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 19, 2026, 6:13 AM EDT
Terminated Phase 1 Interventional

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

NCT00254618
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Delaware Physical Exercise and Activity for Knee Osteoarthritis

NCT04980300
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Intervention, Control
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
45 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

NCT01130844
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
5 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
Little Rock, Arkansas • Anaheim, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Correlation of Mesalamine Pharmacokinetics With Local Availability

NCT01999400
View directory record Official record
Conditions
Local Drug Concentration in Gastrointestinal Tract
Interventions
Pentasa 500 mg capsule x 2 with 240 mL water; single dose, Apriso 375 mg capsule x 3 with 240 mL water; single dose, Lialda 1200 mg tablet x 1 with 240 mL water; single dose, Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT03327558
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

NCT00272311
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
Interventions
Aspirin
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

NCT00073021
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
54
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 4 Interventional

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

NCT01938248
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Apixaban, aspirin
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
4,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Mesa, Arizona • Little Rock, Arkansas • Larkspur, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545740
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
46
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 6:13 AM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

NCT00269438
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroids
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 19, 2026, 6:13 AM EDT
Completed No phase listed Observational

Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)

NCT01678300
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 19, 2026, 6:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP

NCT05672030
View directory record Official record
Conditions
Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Interventions
Non-Interventional
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

NCT01393405
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Methotrexate
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
31
States / cities
Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 19, 2026, 6:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hip Arthroscopy Postoperative Opioid Demands

NCT04094701
View directory record Official record
Conditions
Opioid Use, Pain, Femoral Acetabular Impingement, Labral Tear, Glenoid
Interventions
Control Group Regimen, Opioid reduced regimen
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Mesalamine to Reduce T Cell Activation in HIV Infection

NCT01090102
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome
Interventions
Mesalamine (5-aminosalicylic acid, Apriso), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

NCT04149002
View directory record Official record
Conditions
Preterm Birth
Interventions
Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952
View directory record Official record
Conditions
Microscopic Colitis, Diarrhea
Interventions
Mesalamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 19, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

NCT00350415
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
78
States / cities
Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 19, 2026, 6:13 AM EDT